Monopar Therapeutics Inc. (MNPR) Stock

Monopar Therapeutics Inc. (MNPR) is a Healthcare stock trading at $67.19 (as of 2026-06-18), with a market capitalization of $435.71M and a trailing P/E of -30.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cancer-related treatments in the United States. Its pipeline includes Validive for preventing severe oral mucositis in oropharyngeal cancer, Camsirubicin for advanced soft tissue sarcoma, and MNPR-101 and related radioimmunotherapies for other cancer and severe COVID-19 indications.

Valuation — source: SEC EDGAR (first-party)
Price	$67.19
Market Cap	$435.71M
P/E Ratio	-30.2
Price / Book	3.34
Price / Sales	-757.29
DCF Value (model)	$-21.80
DCF Upside vs Price	-132.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-11.1%
Current Ratio	56.04

Financial Health — source: SEC EDGAR
Altman Z-Score	93.23 (safe)

Valuation vs Sector & Industry
Stock P/E	-30.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-244.4%
vs Industry	-277.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($72.06M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Chandler D. Robinson
Employees	14
Country	US
IPO Date	2019-12-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.